DASH
Repository logo
Communities & Collections
Browse DASH
DASH Stories
Statistics
  1. Home
  2. Harvard Medical School
  3. HMS Scholarly Articles
  4. Activin–like kinase–3 activity is important for kidney regeneration and reversal of fibrosis

Activin–like kinase–3 activity is important for kidney regeneration and reversal of fibrosis

Open/View files
3998727.pdf (4.15 MB)
Date
2014
Author(s)
Sugimoto, Hikaru
LeBleu, Valerie S.
Basukonda, Dattatreyamurty
Keck, Peter
Taduri, Gangadhar
Bechtel, Wibke
Okada, Hirokazu
Bey, Philippe
Rusckowski, Mary
Tampe, Björn
Tampe, Desiree
Kanasaki, Keizo
Zeisberg, Michael
Kalluri, Raghu
DOI
10.1038/nm.2629
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Sugimoto, H., V. S. LeBleu, D. Basukonda, P. Keck, G. Taduri, W. Bechtel, H. Okada, et al. 2014. “Activin–like kinase–3 activity is important for kidney regeneration and reversal of fibrosis.” Nature medicine 18 (3): 396-404. doi:10.1038/nm.2629. http://dx.doi.org/10.1038/nm.2629.
Abstract
Molecules associated with TGF-β superfamily such as BMPs and TGF-β are key regulators of inflammation, apoptosis and cellular transitions. Here, we demonstrate that the BMP receptor activin–like kinase 3 (Alk3) is elevated early in response to kidney injury and its deletion in the tubular epithelium leads to enhanced TGF-β1 / Smad3 signaling, epithelial damage and fibrosis, suggesting a protective role for Alk3 mediated signaling. Structure–function analysis of Alk3 / BMP / BMPRII ligand–receptor complex coupled with synthetic organic chemistry led us to construct a library of small peptide agonists of BMP signaling that function via Alk3 receptor. One such peptide agonist, THR–123, suppressed inflammation, apoptosis epithelial–to–mesenchymal transition program, and reversed fibrosis in mouse models of acute and chronic injury. Combining THR–123 and angiotensin–converting enzyme inhibitor, captopril, exhibited additive therapeutic benefit in controlling fibrosis. Our studies demonstrate that BMP signaling agonists constitute a new line of therapeutic agents with a potential utility in the clinic to induce regeneration, repair and reverse fibrosis.
Other Available Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998727/pdf/
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service
URI
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12153002
Collection
HMS Scholarly Articles
Metrics
Repository logo
  • CONTACT US
  • OSRDS
  • ABOUT DASH
  • DEPOSITING TO DASH
  • TERMS OF USE
  • REQUEST A WAIVER
  • TAKE DOWN POLICY
  • NAME CHANGE POLICY
  • HARVARD OA POLICIES
  • DASH SUBMITTER AGREEMENT
  • Accessibility
  • Privacy
Creative Commons License BY
Creative Commons Attribution 4.0 International License

Except where otherwise noted, this work is subject to a Creative Commons Attribution 4.0 International License,
which allows anyone to share and adapt our material as long as proper attribution is given.
For details and exceptions, see the Harvard Library Copyright Policy
©2024 Presidents and Fellows of Harvard College.